{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:58:14Z","timestamp":1791907094931,"version":"4.3.4"},"reference-count":31,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1136\/ijgc-2023-005111","type":"journal-article","created":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T23:40:11Z","timestamp":1710891611000},"page":"840-846","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Prognostic role of transcription factor ARID1A in patients with endometrial cancer of no specific molecular profile (NSMP) subtype"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3668-442X","authenticated-orcid":false,"given":"Arina","family":"Onoprienko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerda","family":"Hofstetter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonhard","family":"Muellauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Dorittke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Polterauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2948-8129","authenticated-orcid":false,"given":"Christoph","family":"Grimm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1938-1574","authenticated-orcid":false,"given":"Thomas","family":"Bartl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2023-005111_bb0010","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Cancer Genome Atlas Research Network","year":"2013","journal-title":"Nature"},{"key":"10.1136\/ijgc-2023-005111_bb0015","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/ijgo.14923","article-title":"FIGO staging of endometrial cancer: 2023","volume":"162","author":"Berek","year":"2023","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1136\/ijgc-2023-005111_bb0020","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1097\/PAS.0b013e31827f576a","article-title":"Poor interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma","volume":"37","author":"Gilks","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"10.1136\/ijgc-2023-005111_bb0025","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1038\/modpathol.2013.102","article-title":"Reproducibility of histological cell type in high-grade endometrial carcinoma","volume":"26","author":"Han","year":"2013","journal-title":"Mod Pathol"},{"key":"10.1136\/ijgc-2023-005111_bb0030","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1200\/JCO.20.00549","article-title":"Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy","volume":"38","author":"Le\u00f3n-Castillo","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-005111_bb0035","doi-asserted-by":"crossref","first-page":"102287","DOI":"10.1016\/j.ctrv.2021.102287","article-title":"Targeting ARID1A mutations in cancer","volume":"100","author":"Mullen","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"10.1136\/ijgc-2023-005111_bb0040","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.canlet.2020.01.001","article-title":"ARID1A deficiency and immune checkpoint blockade therapy: from mechanisms to clinical application","volume":"473","author":"Hu","year":"2020","journal-title":"Cancer Lett"},{"key":"10.1136\/ijgc-2023-005111_bb0045","doi-asserted-by":"crossref","first-page":"776","DOI":"10.7150\/jca.41296","article-title":"Pan-cancer analysis of ARID1A alterations as biomarkers for immunotherapy outcomes","volume":"11","author":"Jiang","year":"2020","journal-title":"J Cancer"},{"key":"10.1136\/ijgc-2023-005111_bb0050","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000438","article-title":"ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1\/PD-L1 immunotherapy","volume":"8","author":"Okamura","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1136\/ijgc-2023-005111_bb0055","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.ygyno.2021.07.005","article-title":"ARID1A mutation\/ARID1A loss is associated with a high immunogenic profile in clear cell ovarian cancer","volume":"162","author":"Kuroda","year":"2021","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-005111_bb0060","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41571-020-0357-3","article-title":"The SWI\/SNF complex in cancer - biology, biomarkers and therapy","volume":"17","author":"Mittal","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1136\/ijgc-2023-005111_bb0065","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/path.2911","article-title":"Loss of BAF250A (ARID1A) is frequent in high-grade endometrial carcinomas","volume":"224","author":"Wiegand","year":"2011","journal-title":"J Pathol"},{"key":"10.1136\/ijgc-2023-005111_bb0070","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/PAS.0b013e318212782a","article-title":"Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma","volume":"35","author":"Guan","year":"2011","journal-title":"Am J Surg Pathol"},{"key":"10.1136\/ijgc-2023-005111_bb0075","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/annonc\/mdv484","article-title":"ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up","volume":"27","author":"Colombo","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2023-005111_bb0080","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/ijgc-2020-002230","article-title":"ESGO\/ESTRO\/ESP guidelines for the management of patients with endometrial carcinoma","volume":"31","author":"Concin","year":"2021","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2023-005111_bb0085","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1309\/AJCP77GXYVEQXMXT","article-title":"Canadian Association of Pathologists\u2013Association Canadienne des Pathologistes National Standards Committee for High Complexity Testing\/Immunohistochemistry: guidelines for the preparation, release, and storage of unstained archived diagnostic tissue sect","volume":"142","author":"Cheung","year":"2014","journal-title":"Am J Clin Pathol"},{"key":"10.1136\/ijgc-2023-005111_bb0090","doi-asserted-by":"crossref","first-page":"546","DOI":"10.18632\/oncotarget.503","article-title":"Dramatic reduction of sequence artefacts from DNA isolated from formalin-fixed cancer biopsies by treatment with uracil-DNA glycosylase","volume":"3","author":"Do","year":"2012","journal-title":"Oncotarget"},{"key":"10.1136\/ijgc-2023-005111_bb0095","doi-asserted-by":"crossref","DOI":"10.3390\/jpm10040188","article-title":"Targeted therapy recommendations for therapy refractory solid tumors-data from the real-world precision medicine platform MONDTI","volume":"10","author":"Taghizadeh","year":"2020","journal-title":"J Pers Med"},{"key":"10.1136\/ijgc-2023-005111_bb0100","doi-asserted-by":"crossref","DOI":"10.3390\/jpm11010048","article-title":"Risk reclassification of patients with endometrial cancer based on tumor molecular profiling: first real world data","volume":"11","author":"Oberndorfer","year":"2021","journal-title":"J Pers Med"},{"key":"10.1136\/ijgc-2023-005111_bb0105","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/path.5372","article-title":"Interpretation of somatic POLE mutations in endometrial carcinoma","volume":"250","author":"Le\u00f3n-Castillo","year":"2020","journal-title":"J Pathol"},{"key":"10.1136\/ijgc-2023-005111_bb0110","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/path.5373","article-title":"Clinicopathological and molecular characterisation of \u201cmultiple-classifier\u201d endometrial carcinomas","volume":"250","author":"Le\u00f3n-Castillo","year":"2020","journal-title":"J Pathol"},{"key":"10.1136\/ijgc-2023-005111_bb0115","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3802\/jgo.2014.25.1.58","article-title":"Decreased ARID1A expression is correlated with chemoresistance in epithelial ovarian cancer","volume":"25","author":"Yokoyama","year":"2014","journal-title":"J Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-005111_bb0120","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.humpath.2012.11.007","article-title":"Loss of ARID1A\/BAF250A expression is linked to tumor progression and adverse prognosis in cervical cancer","volume":"44","author":"Cho","year":"2013","journal-title":"Hum Pathol"},{"key":"10.1136\/ijgc-2023-005111_bb0125","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1002\/jcb.26109","article-title":"Prognostic and clinicopathological significance of ARID1A in endometrium-related gynecological cancers: a meta-analysis","volume":"118","author":"Liu","year":"2017","journal-title":"J Cell Biochem"},{"key":"10.1136\/ijgc-2023-005111_bb0130","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/modpathol.2012.174","article-title":"ARID1A loss is prevalent in endometrial hyperplasia with atypia and low-grade endometrioid carcinomas","volume":"26","author":"Werner","year":"2013","journal-title":"Mod Pathol"},{"key":"10.1136\/ijgc-2023-005111_bb0135","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.humpath.2012.04.021","article-title":"Clinicopathologic analysis of loss of AT-rich interactive domain 1A expression in endometrial cancer","volume":"44","author":"Rahman","year":"2013","journal-title":"Hum Pathol"},{"key":"10.1136\/ijgc-2023-005111_bb0140","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1097\/IGC.0000000000000092","article-title":"The clinicopathologic significance of the loss of BAF250A (ARID1A) expression in endometrial carcinoma","volume":"24","author":"Zhang","year":"2014","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2023-005111_bb0145","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13050950","article-title":"ARID1A and CTNNB1\/\u0392-catenin molecular status affects the clinicopathologic features and prognosis of endometrial carcinoma: implications for an improved surrogate molecular classification","volume":"13","author":"De Leo","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1136\/ijgc-2023-005111_bb0150","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1136\/ijgc-2023-004360","article-title":"Biomarkers for checkpoint inhibitor therapy in mucinous epithelial ovarian cancer","volume":"33","author":"Bartl","year":"2023","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2023-005111_bb0155","doi-asserted-by":"crossref","first-page":"592","DOI":"10.3390\/diagnostics12030592","article-title":"Relevance of ARID1A mutations in endometrial carcinomas","volume":"12","author":"De Leo","year":"2022","journal-title":"Diagnostics"},{"key":"10.1136\/ijgc-2023-005111_bb0160","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/cjp2.103","article-title":"Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers","volume":"4","author":"Khalique","year":"2018","journal-title":"J Pathol Clin Res"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24014117?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24014117?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2023-005111","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T01:30:06Z","timestamp":1753234206000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24014117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S1048891X24014117"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2023-005111","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic role of transcription factor ARID1A in patients with endometrial cancer of no specific molecular profile (NSMP) subtype","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2023-005111","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 IGCS and ESGO 2024. No commercial re-use. See rights and permissions. Published by BMJ.","name":"copyright","label":"Copyright"}]}}